Chemical compound extends survival by months, in mice
Pancreatic cancer is especially challenging to treat – only eight percent of patients are still alive five years after diagnosis. Chemotherapy and radiation therapy are of limited benefit, and even immunotherapy – which revolutionized treatment for other kinds of cancer by activating the body’s immune system to attack cancer cells – has been largely ineffective because pancreatic tumors have ways to dampen the immune assault.
Now, researchers at Washington University School of Medicine in St. Louis and Rush University in Chicago have found a chemical compound that promotes a vigorous immune assault against the deadly cancer. Alone, the compound reduces pancreatic tumor growth and metastases in mice. But when combined with immunotherapy, the compound significantly shrank tumors and dramatically improved survival in the animals.
The findings, published July 3 in Science Translational Medicine, suggest that the immune-boosting compound could potentially make resistant pancreatic cancers susceptible to immunotherapy and improve treatment options for people with the devastating disease.
“Pancreatic cancer is a highly lethal disease, and we are in desperate need of new therapeutic approaches,” said co-senior author David DeNardo, PhD, an associate professor of medicine and of pathology and immunology at Washington University School of Medicine. “In animal studies, this small molecule led to very marked improvements and was even curative in some cases. We are hopeful that this approach could help pancreatic cancer patients.”
On paper, immunotherapies for pancreatic cancer seem like a good idea. The technique works by releasing a brake on specialized immune cells called T cells so they can attack the cancer. In the past, researchers working in the lab found they could release the brake and prod T cells into killing pancreatic cancer cells. But when doctors tried to treat people with pancreatic cancer using immunotherapies, fewer than five percent of patients improved.
This failure of immunotherapy in pancreatic cancer has puzzled scientists. But T cells aren’t the only player in the immune assault on cancer. Myeloid cells, another kind of immune cell found in and around tumors, can either tamp down or ramp up the immune response. They tilt the playing field by releasing immune molecules that affect how many T cells are recruited to the tumor, and whether the T cells show up at the tumors activated and ready to kill, or suppressed and inclined to ignore the tumor cells. In pancreatic tumors, myeloid cells typically suppress other immune cells, undermining the effects of immunotherapy.
DeNardo, co-senior author Vineet Gupta, PhD, of Rush University, and colleagues realized that releasing the brake on T cells might not be enough to treat pancreatic cancer. Unleashing the power of immunotherapy might require also shifting the balance of myeloid cells toward those that activate T cells to attack.
The researchers identified a compound, called ADH-503, that interferes with the migration of myeloid cells. Normally, pancreatic tumors are teeming with myeloid cells that suppress the immune response. When the researchers gave the compound to mice with pancreatic cancer, the number of myeloid cells in and near the tumors dropped, and the remaining myeloid cells were of the kind that promoted, rather than suppressed, immune responses. This environment translated into greater numbers of cancer-killing T cells in the tumor, significantly slower tumor growth and longer survival.
Then, the researchers – including first author Roheena Panni, MD, resident in general surgery at Washington University and Barnes-Jewish Hospital, and co-author William Hawkins, MD, the Neidorff Family and Robert C. Packman Professor of Surgery at Washington University School of Medicine – investigated whether creating this same environment could make pancreatic tumors susceptible to standard immunotherapy. First, they treated mice with a so-called PD-1 inhibitor, a standard immunotherapy used to treat other kinds of cancer. Unsurprisingly, they saw no effect. But when the researchers gave the mice the immunotherapy in conjunction with ADH-503, the tumors shrank and the mice survived significantly longer. In some experiments, all the tumors disappeared within a month of treatment, and all the mice survived for four months, when the researchers stopped monitoring them. In comparison, all the untreated mice died within six weeks.
Gupta noted that while pancreatic cancer is the third leading cause of cancer-related death in the United States, only about three percent of clinical trials for cancer immunotherapies target pancreatic cancer.
“Unlocking the promise of immunotherapies for pancreatic cancer requires a new approach,” Gupta said. “We believe these data demonstrate that targeting myeloid cells can help overcome resistance to immunotherapies.”
The strategy of boosting antitumor immune activity by shifting the balance of myeloid cells improved the effectiveness of other pancreatic cancer therapies as well, the researchers said. Mice treated with chemotherapy or radiation therapy both fared significantly better when ADH-503 was added to the regimen.
“You can’t make a one-to-one translation between animal studies and people, but this is very encouraging,” DeNardo said. “More study is needed to understand if the compound is safe and effective in people, which is why Gossamer Bio, Inc., is starting phase I safety studies in people later this year at Washington University and other sites.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Polymer coated gold nanoshells for combinational photochemotherapy of pancreatic cancer with gemcitabineon April 30, 2021 at 11:51 am
Pancreatic cancer is one of the most lethal malignancies with limited therapeutic options and dismal prognosis. Gemcitabine is the front-line drug against pancreatic cancer however with limited ...
- Galera Posts Positive Data from Phase 1/2 Pancreatic Cancer Trialon April 30, 2021 at 10:58 am
Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was ...
- Risk of cancer development in patients with keloidson April 30, 2021 at 10:48 am
As keloids are a prototypic fibroproliferative disease, this study investigated whether patients with keloids have an increased cancer risk. In a matched, population-based study, first 17,401 patients ...
- Pancreatic Cancer During the Pandemicon April 30, 2021 at 5:19 am
Barbara Wojciechowski was diagnosed with pancreatic cancer as the pandemic was rising, affecting her family support during treatment.
- Stage 4 Pancreatic Cancer Survival Rateson April 29, 2021 at 7:43 am
Stage 4 pancreatic cancer is when cancer has spread from the pancreas to distant organs. While it is the most advanced stage, there are treatment options.
- Pancreatic cancer cells de-differentiate to spawn highly aggressive tumors, study showson April 28, 2021 at 10:57 pm
A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert-or "de-differentiate"-to ...
- Scientists Shrink Pancreatic Cancer Tumors by Starving Their Cellular “Neighbors”on April 28, 2021 at 10:08 pm
Scientists at Sanford Burnham Prebys Medical Discovery Institute demonstrated for the first time that blocking "cell drinking," or macropinocytosis, in the thick tissue surrounding a pancreatic tumor ...
- A Pancreatic Cancer Oncologist Addresses Health Equityon April 26, 2021 at 6:07 am
Dr. Edith Mitchell of Thomas Jefferson University shares what led her to devote her career to medicine and why pancreatic cancer may affect minorities disproportionately.
- Scientists Predict Rise In Deaths From Pancreatic Cancer And Young-Onset Colorectal Canceron April 24, 2021 at 11:40 am
Colorectal cancer is predicted to become the leading cause of cancer death for young people between the ages of 20 and 49.
- Margin-positive surgery still beneficial in pancreatic canceron April 22, 2021 at 9:54 am
(HealthDay)—For patients with stage II pancreatic cancer, attempted surgery with margin-positive resection may offer survival benefit over chemotherapy alone, according to a study published online ...
via Bing News